香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而 產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Sinopharm Tech Holdings Limited 國藥科技股份有限公司 ( 於開曼群島註冊成立之有限公司 ) (股份代號: 8156) 更換公司秘書 國藥科技股份有限公司（「本公司」）之董事（「董事」）會（「董事會」）謹此宣佈 黃子玲女士（「黃女士」）已辭任本公司公司秘書（「公司秘書」），自二零二五年十 月二十三日起生效。黃女士已確認其與董事會概無意見分歧，亦無其他與其辭任有關的 事項需要通知香港聯合交易所有限公司或本公司股東。 董事會進一步宣佈郭祖貽先生（「郭先生」）已獲委任為公司秘書，自二零二五年十月 二十三日起生效。 郭先生為香港會計師公會及澳洲會計師公會會員。郭先生於香港及澳洲擁有逾20年會 計、核數、財務及公司秘書領域的經驗。彼於澳洲悉尼科技大學取得會計及財務碩士學 位，並於澳洲麥覺理大學取得工商管理學士學位。 董事會謹藉此機會對黃女士在任期間對本公司所作出之寶貴貢獻致以讚賞及謝意 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 國藥科技股份有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08156 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 12,800,000,000 | HKD | | 0.0125 | HKD | | 160,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 12,800,000,000 | HKD | | 0.0125 | HKD | | 160,000,000 | | ...

Group 1 - The core viewpoint of the article highlights that China National Pharmaceutical Group Technology Co., Ltd. (国药科技股份) reported a significant improvement in its financial performance for the year ending June 30, 2025, with revenue reaching approximately HKD 61.3 million, representing a year-on-year increase of about 48% [1] - The company reported a loss attributable to shareholders of approximately HKD 0.9 million, which is a substantial reduction of about 95% compared to the previous year [1] - The increase in revenue is primarily attributed to the rising demand in the health products market and improved operational efficiency in supply chain services, underscoring the effectiveness of the company's strategic focus on these core business areas [1] Group 2 - The board of directors noted that the significant improvement in the group's financial performance this year is mainly due to several net impacts, including a gross profit increase of approximately HKD 9.2 million or 184% year-on-year due to business improvements [1] - The company has strengthened cost control over administrative and operational expenses [1] - The company recorded capitalized loan income of approximately HKD 3.9 million this year, which contributed to a reduction in financing costs due to the capitalized loans [1]

Core Viewpoint - China National Pharmaceutical Group Technology Co., Ltd. (国药科技股份) reported a significant improvement in its financial performance for the year ending June 30, 2025, with a revenue increase of approximately 48% year-on-year, reaching about HKD 61.3 million, and a substantial reduction in net loss by about 95% to approximately HKD 0.9 million [1] Financial Performance - Revenue for the year was approximately HKD 61.3 million, representing a year-on-year increase of about 48% [1] - The loss attributable to owners was approximately HKD 0.9 million, a significant decrease of about 95% compared to the previous year [1] - Earnings per share reflected a loss of HKD 0.0019 [1] Factors Contributing to Performance - The revenue growth was primarily driven by increased demand in the health products market and improved operational efficiency in supply chain services, highlighting the effectiveness of the company's strategic focus on these core business areas [1] - The board noted several key factors contributing to the improved financial performance, including: - A year-on-year gross profit increase of approximately HKD 9.2 million or 184% due to business improvements [1] - Enhanced cost control over administrative and operational expenses [1] - Capitalized loan income of approximately HKD 3.9 million for the year [1] - Reduced financing costs due to loan capitalization during the year [1]

Financial Performance - For the fiscal year ending June 30, 2025, the company experienced significant revenue growth driven by increased demand for health products, improved supply chain efficiency, and optimized service processes[8]. - The company recorded revenue of approximately HKD 61,300,000 for the year, an increase of about 48% compared to HKD 41,200,000 in the same period of 2024[18]. - Gross profit for the year was approximately HKD 14,200,000, representing an increase of about 184% from HKD 5,000,000 in the previous year, driven by higher gross margins in health product supply chain services[18]. - The company reported a loss attributable to shareholders of approximately HKD 900,000, significantly reduced by about 95% from a loss of HKD 19,700,000 in the previous year[18]. - The supply chain services segment generated revenue of approximately HKD 61,300,000, with a gross margin of about 23%, compared to a gross margin of 12% in the previous year[21]. Strategic Focus and Operations - The company has strategically paused investments in the "Internet+" solutions and personal protective equipment sectors, focusing resources on high-growth areas such as AI applications and pharmaceutical sales[8]. - The company aims to strengthen its core competitiveness by reallocating resources towards high-potential areas within the health industry and supply chain services[12]. - The company plans to focus on the health industry and supply chain services, with an emphasis on AI applications in healthcare, life sciences, and data science[14]. - The company is committed to continuing its digital transformation and AI-driven operations to achieve long-term value growth[11]. - The integration of data-driven market insights has effectively assisted clients in seizing business opportunities, contributing to the company's growth[10]. Financial Management and Capital Structure - The company will continue to optimize its capital structure and strictly control financial risks to support future business expansion[17]. - The group completed a capital restructuring and loan capitalization, reducing debt burden by approximately HKD 193,000,000, which strengthens the equity base for future growth[31]. - Current liabilities significantly decreased to approximately HKD 68,400,000 from HKD 249,400,000 in 2024, reflecting successful debt management and balance sheet optimization[26]. - The capital debt ratio improved to approximately 9% as of June 30, 2025, compared to 162% in 2024, demonstrating enhanced financial stability[26]. - The group remains focused on maintaining sufficient liquidity to support ongoing operations and strategic initiatives while ensuring prudent financial management[27]. Corporate Governance - The board is committed to maintaining high levels of corporate governance and effective accountability systems to protect shareholder interests and promote business growth[42]. - The company has adopted the GEM Listing Rules Appendix C1 Corporate Governance Code, with some deviations noted, particularly regarding the separation of the roles of Chairman and CEO[43]. - The roles of Chairman and CEO are currently held by executive directors, which the board believes benefits the company's business prospects and management[47]. - The company will periodically review and update its corporate governance practices to comply with GEM Listing Rules as deemed appropriate[45]. - The company has established mechanisms to ensure independent insights and input for the board, including annual reviews of board structure and diversity policies[53]. Risk Management - The company faces risks related to fluctuations in market demand for health products and pharmaceuticals, which are influenced by consumer preferences and macroeconomic trends[94]. - The company has implemented AI demand forecasting and dynamic inventory mechanisms to enhance operational efficiency and cost control[95]. - The board conducts an annual review of the effectiveness of the risk management and internal control systems, covering financial, operational, and compliance monitoring[70]. - The company has established a comprehensive risk management and internal control system to ensure the reliability of financial information and prevent fraud[67]. - The company continues to seek alternative financing and bank loans to settle existing financial obligations and fund future operations and capital expenditures[68]. Environmental, Social, and Governance (ESG) Initiatives - The company has implemented energy-saving measures to reduce greenhouse gas emissions, which are the primary source of its carbon footprint[168]. - The company has adopted responsible waste management policies to minimize waste generation and ensure proper disposal[168]. - The company has committed to reducing greenhouse gas emissions and waste generation as part of its environmental, social, and governance (ESG) initiatives[185]. - The company has not produced any packaging materials for finished products this year, maintaining a density of 0 tons per business unit[183]. - The company has set a target to keep air pollutants and greenhouse gas emissions at or below the levels recorded as of June 30, 2020[175]. Employee Management and Development - The total number of employees as of June 30, 2025, is 33, with 19 males and 13 females[190]. - Employee turnover rate for males is 5.13% as of June 30, 2025, down from 30.30% in the previous year[191]. - The company provides various healthcare plans and has implemented COVID-19 preventive measures for employee safety[195]. - The company encourages employee development through external training and continuous education opportunities[196]. - Percentage of trained employees is 78.95% for males and 100% for females as of June 30, 2025[198].

Financial Performance - For the fiscal year ending June 30, 2025, the company reported a significant revenue growth driven by the increasing demand for health products, improved supply chain efficiency, and optimized service processes[11]. - The company recorded revenue of approximately HKD 61.3 million for the year, an increase of about 48% compared to HKD 41.2 million in the same period last year, driven by increased demand for health products and improved supply chain efficiency[21]. - Gross profit for the year was approximately HKD 14.2 million, up about 184% from HKD 5 million in the previous year, primarily due to higher gross margins from health product supply chain services[21]. - The company reported a loss attributable to shareholders of approximately HKD 900,000, a significant reduction of about 95% compared to a loss of HKD 19.7 million in the previous year, reflecting improved financial performance[21]. Strategic Focus - The company has paused resource allocation to "Internet+" solutions and personal protective equipment businesses, focusing instead on core growth areas in the health industry and supply chain services[11]. - The company aims to concentrate resources on high-potential areas such as "AI+ business applications" and pharmaceutical sales to strengthen its long-term competitive advantage[11]. - The company is focusing on digital transformation and AI operations in its core business to achieve long-term value growth[14]. - The company plans to deepen strategic resource investment and expand its business coverage in the health product and supply chain service sectors[17]. - The company is actively exploring new growth paths in AI solutions for health and medical supply chains, aiming to build a diversified and sustainable business portfolio[20]. Operational Efficiency - The organization is optimizing its structure and integrating human resources, which has improved cross-departmental collaboration and reduced administrative costs[12]. - The company will continue to optimize its internal organizational structure and enhance operational efficiency, leading to a significant reduction in administrative and operational costs[16]. - The company aims to integrate AI into key operational areas such as market trend forecasting and supply chain management to enhance service quality and operational efficiency[18]. Corporate Governance - The board is committed to maintaining high levels of corporate governance to protect shareholder interests and enhance business growth[45]. - The company emphasizes a high-quality board composition and effective accountability systems[45]. - The company has adopted and complied with the Corporate Governance Code under GEM Listing Rules Appendix C1, with the exception of certain deviations[46]. - The board consists of three independent non-executive directors, representing at least one-third of the board members, with at least one possessing appropriate professional qualifications or financial management expertise[55]. - The board is responsible for reviewing the group's financial performance and approving strategic plans, major investments, and risk management policies[54]. Risk Management - The board has established a comprehensive risk management and internal control system to manage risks associated with achieving the group's strategic objectives[70]. - The internal audit function is in place to analyze and independently assess the effectiveness of the risk management and internal control systems[73]. - The company faces risks related to market demand fluctuations, supply chain and cost control, product quality and compliance, and technology integration and digital transformation[97][98][100][101]. Environmental, Social, and Governance (ESG) - The company has implemented energy-saving measures to reduce greenhouse gas emissions, primarily from indirect emissions due to daily electricity consumption[171]. - The total indirect carbon dioxide emissions from electricity procurement were 5.59 tons in Hong Kong and 18.41 tons in China for the year ended June 30, 2025, compared to 7.97 tons and 23.91 tons respectively for the previous year[175]. - The company produced zero tons of non-hazardous waste during the reporting year, maintaining the same level as the previous year[177]. - The company has not identified any significant non-compliance with environmental laws and regulations in Hong Kong and China during the reporting year[171]. - The company has established effective communication with stakeholders to understand their needs and concerns regarding environmental, social, and governance factors[166]. Employee Management - The total employee cost for the year was approximately HKD 3,300,000, a decrease from HKD 3,500,000 in the previous year[38]. - The company employed 32 employees as of June 30, 2025, down from 33 in the previous year[38]. - Employee turnover rate for males decreased to 5.13% in 2025 from 30.30% in 2024, while females remained at 0.00%[194]. - Continuous employee development is a key factor for the company's success, with on-the-job training and encouragement for external training participation[199]. - The company ensures compliance with health and safety regulations, with no significant violations reported during the year[196]. Shareholder Communication and Dividends - The company has established a shareholder communication policy to ensure timely and balanced information dissemination regarding financial performance and strategic objectives[89]. - The board does not recommend the distribution of any dividends for the current year[106]. - The company has adopted a dividend policy, allowing for the declaration and distribution of final, interim, or special dividends as determined by the board, subject to shareholder approval[107]. Debt Management and Capital Structure - The company completed a capital restructuring and loan capitalization, reducing debt burden by approximately HKD 193 million, strengthening its equity base for future growth[34]. - Current liabilities significantly decreased to approximately HKD 68.4 million from HKD 249.4 million in the previous year, reflecting successful debt management[29]. - Capital debt ratio improved to about 9% from 162% in the previous year, showcasing the company's efforts to optimize its capital structure[29]. Audit and Compliance - The financial statements for the year have been audited by Suya Wenshun CPA Limited, with the previous auditor, Yongtuo Fuxin CPA Limited, resigning on June 24, 2025[160]. - The audit committee conducted five meetings to review financial reporting and internal control systems[60]. - The independent auditor's report indicates that the financial statements reflect the group's financial position as of June 30, 2025, except for certain matters noted[74].

Core Viewpoint - The company, China National Pharmaceutical Group Technology Co., Ltd. (08156.HK), anticipates a significant reduction in losses for the fiscal year ending June 30, 2025, projecting a loss of no more than HKD 1 million, compared to a loss of approximately HKD 19.7 million for the fiscal year ending June 30, 2024, representing a decrease of about 95% [1] Financial Performance - The expected financial improvement is attributed to several factors, including: - A year-on-year increase in gross profit of approximately HKD 9.2 million or 184% due to business improvements [1] - Enhanced cost control measures in administrative and operational expenditures [1] - Capitalized loan income of approximately HKD 3.9 million during the reporting period [1] - A reduction in financing costs resulting from loan capitalization during the reporting period [1]

Core Viewpoint - The company expects to achieve a loss attributable to shareholders of no more than 1 million HKD for the fiscal year ending June 30, 2025, representing a significant reduction of approximately 95% year-on-year [1] Financial Performance - The company's financial performance has significantly improved during the reporting period, primarily due to several factors [1] - Business improvements led to a gross profit increase of approximately 9.2 million HKD or 184% year-on-year [1] - Enhanced cost control measures for administrative and operational expenses contributed positively [1] - The company recognized loan capitalization gains of approximately 3.9 million HKD during the reporting period [1] - Financing costs decreased due to the loan capitalization, further aiding financial performance [1]

智通财经APP讯，国药科技股份(08156)公布，预期该集团截至2025年6月30日止年度将取得公司拥有人 应占亏损不超过100万港元，同比大幅减少约95%。董事会认为本集团于本报告期内财务表现大幅改善 主要归因于(其中包括)以下因素的净影响：(i) 业务改善导致毛利同比增加约920万港元或184%;(ii) 加强 行政及营运开支的成本控制;(iii) 本报告期内贷款资本化收益约390万港元;及 (iv) 由于贷款资本化导致本 报告期内融资成本减少。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Sinopharm Tech Holdings Limited 國藥科技股份有限公司 -1- 在投資者應參閱本集團於本報告期內的全年業績初步公告，預期該公告將於二零 二五年九月二十六日或左右刊發。 本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 Sinopharm Tech Holdings Limited 國藥科技股份有限公司 執行董事 趙善能 ( 於開曼群島註冊成立之有限公司 ) (股份代號: 8156) 盈利預告 虧損大幅減少 本公告乃國藥科技股份有限公司（「本公司」，連同其附屬公司統稱「本集團」） 根據香港聯合交易所有限公司GEM證券上市規則（「GEM上市規則」）第17.10 條及香港法例第571章證券及期貨條例第XIVA部之內幕消息條文（定義見GEM 上市規則）而作出。 本公司董事（「董事」）會（「董事會」）欣然通知本公司股東及潛在投資者， 根據對本集團截至二零二五年六月三十 ...